2021
Immunomodulation by Mosquito Salivary Protein AgSAP Contributes to Early Host Infection by Plasmodium
Arora G, Sajid A, Chuang YM, Dong Y, Gupta A, Gambardella K, DePonte K, Almeras L, Dimopolous G, Fikrig E. Immunomodulation by Mosquito Salivary Protein AgSAP Contributes to Early Host Infection by Plasmodium. MBio 2021, 12: e03091-21. PMID: 34903042, PMCID: PMC8669493, DOI: 10.1128/mbio.03091-21.Peer-Reviewed Original ResearchConceptsLocal inflammatory responsePlasmodium berghei sporozoitesSalivary antigensInflammatory responseBerghei sporozoitesPlasmodium falciparumMosquito salivary proteinsPrevention of malariaLocal host responseAnopheline mosquitoesVertebrate hostsHost responseSaliva secretionVaccine developmentMalariaEpidemiological analysisGenerate antibodiesAntigenArthropod salivaDisease prevalenceInfectionSaliva componentsSporozoitesVector-borne diseasesDisease
2020
Antibiotic Treatment Shapes the Antigenic Environment During Chronic TB Infection, Offering Novel Targets for Therapeutic Vaccination
Chuang YM, Dutta NK, Gordy JT, Campodónico VL, Pinn ML, Markham RB, Hung CF, Karakousis PC. Antibiotic Treatment Shapes the Antigenic Environment During Chronic TB Infection, Offering Novel Targets for Therapeutic Vaccination. Frontiers In Immunology 2020, 11: 680. PMID: 32411131, PMCID: PMC7198710, DOI: 10.3389/fimmu.2020.00680.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntigens, BacterialAntitubercular AgentsBacterial ProteinsCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesCell LineChronic DiseaseDrug Resistance, BacterialFemaleGuanosine PentaphosphateGuinea PigsHydrolasesIsoniazidLigasesMacrophagesMiceMice, Inbred C57BLMycobacterium tuberculosisTreatment OutcomeTuberculosisTuberculosis VaccinesVaccinationVaccines, DNAConceptsTherapeutic vaccinationDNA vaccineT cellsC57BL/6 miceMtb persistersGuinea pigsAntigenic environmentFirst-line anti-TB drugsChronic TB infectionDrug-susceptible tuberculosisLung bacterial burdenAnti-TB drugsSpleens of miceHartley guinea pigsActivity of isoniazidAntitubercular treatmentReactive CD4Reactive CD8TB chemotherapyTB infectionTB treatmentCurrent regimenDaily dosesBacterial burdenIsoniazid treatment